The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 19, 2016
Filed:
May. 23, 2012
Applicants:
Stephen E. Zale, Hopkinton, MA (US);
Greg Troiano, Pembroke, MA (US);
Mir Mukkaram Ali, Woburn, MA (US);
Jeff Hrkach, Lexington, MA (US);
James Wright, Lexington, MA (US);
Inventors:
Stephen E. Zale, Hopkinton, MA (US);
Greg Troiano, Pembroke, MA (US);
Mir Mukkaram Ali, Woburn, MA (US);
Jeff Hrkach, Lexington, MA (US);
James Wright, Lexington, MA (US);
Assignee:
BIND Therapeutics, Inc., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/14 (2006.01); A61K 47/34 (2006.01); A61K 9/10 (2006.01); A61K 9/19 (2006.01); A61K 9/51 (2006.01); A61K 31/337 (2006.01); A61K 31/436 (2006.01); A61K 31/475 (2006.01); A61K 47/48 (2006.01); B82Y 5/00 (2011.01); A61J 3/00 (2006.01); A61K 31/4355 (2006.01); A61K 31/437 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); A61K 9/16 (2006.01); C07C 59/08 (2006.01);
U.S. Cl.
CPC ...
A61K 47/34 (2013.01); A61J 3/00 (2013.01); A61K 9/10 (2013.01); A61K 9/14 (2013.01); A61K 9/145 (2013.01); A61K 9/146 (2013.01); A61K 9/19 (2013.01); A61K 9/5146 (2013.01); A61K 9/5153 (2013.01); A61K 31/337 (2013.01); A61K 31/436 (2013.01); A61K 31/437 (2013.01); A61K 31/4355 (2013.01); A61K 31/475 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 47/4883 (2013.01); A61K 47/48869 (2013.01); B82Y 5/00 (2013.01); A61K 9/1647 (2013.01); C07C 59/08 (2013.01); Y10S 977/773 (2013.01);
Abstract
The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.